Search

Your search keyword '"Sorasio, R"' showing total 12 results
Start Over Author "Sorasio, R" Language undetermined
12 results on '"Sorasio, R"'

1. Multi-center experience using total lymphoid irradiation and anti-thymocyte globulin as conditioning for allografting in hematological malignancies

Author

Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Selleri C, Levis A, Mordini N, Gallamini A, Pastano R, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B., RISITANO, ANTONIO MARIA, Messina, G, Giaccone, L, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, Gigli, F, Passera, R, Cavattoni, I, Filippi, Ar, Schianca, Fc, Pini, M, Risitano, ANTONIO MARIA, Selleri, C, Levis, A, Mordini, N, Gallamini, A, Pastano, R, Casini, M, Aglietta, M, Montanari, M, Console, G, Boccadoro, M, Ricardi, U, and Bruno, B.

Published
2012

2. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies

Author

Messina, G, Giaccone, Luisa, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, Gigli, F, Passera, R, Cavattoni, I, Filippi, Andrea Riccardo, Schianca, Fc, Pini, M, Risitano, Am, Selleri, C, Levis, A, Mordini, N, Gallamini, A, Pastano, R, Casini, M, Aglietta, Massimo, Montanari, M, Console, G, Boccadoro, Mario, Ricardi, Umberto, Bruno, Benedetto, and Gruppo Italiano Trapianti di Midollo

Subjects
Male, Myeloid, Transplantation Conditioning, Graft vs Host Disease, total lymphoid irradiation, antithymocyte globulin, bone marrow transplantation, Graft-versus-host disease, Gastroenterology, Severity of Illness Index, HLA Antigens, Recurrence, Nonmyeloablative conditioning, biology, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, surgical procedures, operative, medicine.anatomical_structure, Hematologic Neoplasms, Histocompatibility, Cyclosporine, Female, Whole-Body Irradiation, Total lymphoid irradiation/antithymocyte globulin, Adult, medicine.medical_specialty, Globulin, anti-thymocyte globulin, Refractory, Antigen, Internal medicine, medicine, Humans, Transplantation, Homologous, hematological malignancies, Aged, Antilymphocyte Serum, Transplantation, business.industry, Mycophenolic Acid, medicine.disease, Survival Analysis, Anti-thymocyte globulin, Surgery, biology.protein, business
Abstract

A non myeloablative conditioning with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) was shown to protect against graft-versus-host disease (GVHD). To evaluate the effects of TLI-ATG in a multicenter study, 45 heavily pretreated patients, median age 51, with lymphoid (n = 38) and myeloid (n = 7) malignancies were enrolled at 9 centers. Twenty-eight patients (62%) received at least 3 lines of treatment before allografting, and 13 (29%) had refractory/relapsed disease at the time of transplantation. Peripheral blood hematopoietic cells were from HLA identical sibling (n = 30), HLA-matched (n = 9), or 1 antigen HLA-mismatched (n = 6) unrelated donors. A cumulative TLI dose of 8 Gy was administered from day −11 through −1 with ATG at the dose of 1.5 mg/kg/day (from day −11 through −7). GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil. Donor engraftment was reached in 95% of patients. Grade II to IV acute GVHD (aGVHD) developed in 6 patients (13.3%), and in 2 of these patients, it developed beyond day 100. Incidence of chronic GVHD (cGVHD) was 35.8%. One-year nonrelapse mortality was 9.1%. After a median follow-up of 28 months (range, 3-57 months) from transplantation, median overall survival was not reached, whereas median event-free survival was 20 months. This multicenter experience confirms that TLI-ATG protects against GVHD and maintains graft-vs-tumor effects.

Published
2012

3. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

Author

Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mulè A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Stephane Chauvie, and Am, Gianni

Subjects
Adult, Male, Settore MED/06 - Oncologia Medica, Drug Substitution, Middle Aged, Prognosis, Vinblastine, Hodgkin Disease, Dacarbazine, Bleomycin, Treatment Outcome, Doxorubicin, Vincristine, Positron-Emission Tomography, Procarbazine, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Female, Epidemiologic Methods, Settore MED/15 - Malattie del Sangue, Cyclophosphamide, Etoposide
Abstract

Interim 2-[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography performed after two chemotherapy cycles (PET-2) is the most reliable predictor of treatment outcome in ABVD-treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed the treatment outcome of a therapeutic strategy based on PET-2 results: positive patients switched to BEACOPP, while negative patients continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL patients admitted to nine centres were enrolled; 54 patients, unfit to receive this treatment were excluded from the analysis. PET-2 scans were reviewed by a central panel of nuclear medicine experts, according to the Deauville score (Meignan, 2009). After a median follow up of 34 months (12-52) the 2-year failure free survival (FFS) and overall survival for the entire cohort of 165 patients were 88% and 98%; the FFS was 65% for PET-2 positive and 92% for PET-2 negative patients. For 154 patients in which treatment was correctly given according to PET-2 review, the 2-year FFS was 91%: 62% for PET-2 positive and 95% for PET-2 negative patients.this strategy, with BEACOPP intensification only in PET-2 positive patients, showed better results than ABVD-treated historic controls, sparing BEACOPP toxicity to the majority of patients.

Published
2010

4. Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders

Author

Tricot, G, Zangari, M, Sorasio, R, and Bruno, Benedetto

Subjects
Transplantation Conditioning, Plasma Cells, Hematopoietic Stem Cell Transplantation, Middle Aged, Hematopoietic Stem Cells, Ligands, Prognosis, Transplantation, Autologous, Treatment Outcome, Disease Progression, Humans, Renal Insufficiency, Multiple Myeloma, In Situ Hybridization, Fluorescence, Aged
Published
2009

6. A prospective phase II study on tandem autografting - Nonmyeloablative allografting for newly diagnosed multiple myeloma: Final results of a multicenter GITMO (Gruppo Italiano Trapianto Midollo Osseo) protocol

Author

Sorasio, R, Patriarca, F, Giaccone, L, Mattei, D, Allione, B, CARNEVALE SCHIANCA, F, Rambaldi, A, Casini, M, Montefusco, V, Parma, M, Bavaro, F, Onida, F, Busca, A, Castagna, L, Lori, Ap, Rotta, M, Fiore, F, Benedetti, E, Mordini, N, Massaia, M, Palumbo, A, Aglietta, M, Lewis, A, Foa, R, DI BARTOLOMEO, P, Pogliani, E, LAMBERTENGHI DELILIERS, G, Falma, M, Petrini, M, Corradini, F, Fanin, R, Ricardi, U, Ciccone, G, Baldi, Ileana, Bruno, B, and Boccadoro, M.

Published
2007

7. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation

Author

Benedetto Bruno, Patriarca, F., Sorasio, R., Mattei, D., Montefusco, V., Peccatori, J., Bonifazi, F., Petrucci, M. T., Milone, G., Guidi, S., Giaccone, L., Rotta, M., Fanin, R., Boccadoro, M., and Corradini, P.

Subjects
Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Boronic Acids, Dexamethasone, Disease-Free Survival, Bortezomib, Treatment Outcome, Recurrence, Pyrazines, Humans, Transplantation, Homologous, Multiple Myeloma, Retrospective Studies
Abstract

We retrospectively evaluated the efficacy of bortezomib in 23 patients with multiple myeloma who had relapsed after allografting. Bortezomib was given as single agent to 9 patients (39%) and in combination with steroids in the other 14 (61%). Major toxicities were thrombocytopenia (10/23, 43%) and peripheral neuropathy (12/23, 52%). The overall response rate was 61% (14/23), including 22% (5/23) immunofixation-negative complete remissions. No significant differences in toxicity and response rates were seen between patients treated with bortezomib plus steroids and bortezomib alone. After a median follow-up of 6 months, progression free survival was 6 months. Twenty-one patients are alive, two and five in continuous very good partial and complete remissions, respectively.

9. OUTCOME OF ALLOGENEIC-HSCT IN 441 ADULT PATIENTS WITH PH-POSITIVE-ALL IN THE ERA OF TKI: A RETROSPECTIVE ANALYSIS OF THE ITALIAN BLOOD AND MARROW TRANSPLANTATION SOCIETY (GITMO)

Author

Candoni, A., Rambaldi, A., Fanin, R., Velardi, A., Arcese, W., Ciceri, F., Lazzarotto, D., Lussana, F., Olivieri, J., Grillo, G., Parma, M., Bruno, B., Sora, F., Bernasconi, P., Saccardi, R., Foa, R., Sessa, M., Bresciani, P., Giglio, F., Picardi, A., Busca, A., Sica, S., Diral, E., Colombo, A. A., Tringali, S., Santarone, S., Irrera, G., Mancini, S., Zallio, F., Malagola, M., Albano, F., Carella, A. M., Olivieri, A., Tecchio, C., alida dominietto, Vacca, A., Sorasio, R., Orciuolo, E., Risitano, A. M., Cortelezzi, A., Mammoliti, S., Oldani, E., and Bonifazi, F.

10. One-hundred-eight consecutive newly diagnosed multiple myeloma patients treated with the tandem auto-TBI based mini-allo approach

Author

Bruno, B., Patriarca, F., Rotta, M., Maloney, D., Mordini, N., Casini, M., Rambaldi, A., Carnevale-Schianca, F., Allione, B., Soligo, D., Bavero, P., Giaccone, L., Sorasio, R., Montefusco, V., Busca, A., Iori, A., Castagna, L., Edoardo Benedetti, Fabritis, P., Fanin, R., Gallamini, A., Corradini, P., Levis, A., Aglietta, M., Pogliani, E., Falda, M., Petrini, M., Massaia, M., Palumbo, A., Sandmaier, B., Storb, R., and Boccadoro, M.

11. Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study

Author

Pagano, L., Valentini, Cg, Di Paolantonio, G., Melillo, L., Gaidano, G., Venditti, A., Specchia, G., Cattaneo, C., Pica, G., Spadea, A., D’arco, A., Candoni, A., Rodeghiero, F., Abbadessa, A., Piccin, A., Ballerini, F., Sorasio, R., Nosari, A., Caramatti, C., Invernizzi, R., Aversa, F., Pacilli, L., Musto, P., Peli, A., Quintini, G., Forghieri, F., Facchetti, F., Pavan, L., Mannelli, F., Massimiliano BONIFACIO, Leone, G., and Pulsoni, A.

Subjects
blastic plasmacytoid dendritic leukemia, rare disease, chemotherapy

Catalog

Books, media, physical & digital resources
See catalog results